ACR Meeting Abstracts

ACR Meeting Abstracts

Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Treatment Strategies

Date: Sunday, November 13, 2016

Time: 2:30PM-4:00PM

Meeting: 2016 ACR/ARHP Annual Meeting

Abstract Number: 951
A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry
Abstract Number: 952
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Abstract Number: 953
Comparison of 10-Years Disease Outcomes of Rheumatoid Arthritis Patients with Continued Low Disease Activity on Methotrexate with or without Initial Combination Therapy with Infliximab or Prednisone and Sulfasalazine
Abstract Number: 954
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Abstract Number: 955
Tocilizumab Infusion Intervals Can be Extended to 5 or 6 Weeks in RA Patients Who Sustained Low Disease Activity By 4 Weeks Interval of Tocilizumab Infusion
Abstract Number: 956
The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity

« View all sessions from this meeting